EVT-103
EVT-103, also known as ENS-103, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder. It acts as an NMDA receptor subunit 2B (NR2B) antagonist. As of November 2017, no recent reports of development for major depressive disorder have been identified. The drug was developed as a follow-up compound to EVT-101. The chemical structure of EVT-103 has not been released
- Need help finding a doctor or specialist anywhere in the world? WikiMD's DocFinder can help with millions of doctors!
This article is a stub. Help WikiMD grow by registering to expand it. |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Admin, Prab R. Tumpati, MD